HC Wainwright & Co. Maintains Buy on GT Biopharma, Lowers Price Target to $5
HC Wainwright & Co. analyst Robert Burns maintains GT Biopharma (NASDAQ:GTBP) with a Buy and lowers the price target from $25 to $5.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
SenesTech (NASDAQ:SNES) stock rose 28.0% to $0.64 during Thursday's after-market session. The market value of their outstanding shares is at $7.8 million.
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650
GT Biopharma, Inc. (the "Company" or "GTB") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer
GT Biopharma Q2 EPS $(0.10) Up From $(0.15) YoY
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.10) per share. This is a 33.33 percent increase over losses of $(0.15) per share from the same period last year.